Efficacy of Inpatient Infusions for Patients with Chronic Migraine and History of Head Trauma
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- This small pilot study in 53 patients evaluated the effectiveness of inpatient infusions for patients with chronic migraine and a history of head trauma.
- Inpatient infusions of dihydroergotamine, chlorpromazine or valproate sodium should be considered in the management of chronic migraine in patients who have a history of head trauma.
- Treatment outcomes are comparable to the general chronic migraine population undergoing similar infusion admissions.
Presenting Author
Nina Riggins, MD, PhD
Assistant Professor
UCSF Headache Center
San Francisco, California
Nina Riggins, MD, PhD, Assistant Clinical Professor of Neurology at University of California San Francisco, Headache Center
Dr Riggins is Board Certified (Neurology), American Board of Psychiatry and Neurology
Dr Riggins completed Neurology Residency program at Penn State Medical Center, Clinical Neurophysiology Fellowship - at State University of New York, Buffalo and Headache Medicine Fellowship - at University of California, San Francisco.
Dr Riggins is member of AHS, IHS and AAN, she is strong believer in the power of Research, Education and Community, and confident that, by joining together, we can find way to healing.
Non-presenting Author(s)
Annika Ehrlich, MS
Nurse Practitioner
UCSF Headache Center
San Francisco, California
Henna Sawhney, MD
Clinical Research Coordinator
UCSF Headache Center
San Francisco, California
Mira Parekh, PharmD
UCSF Medical Center
San Francisco, California
Morris Levin, MD
Director
UCSF Headache Center
San Francisco, California
Authors disclosures
Nina Riggins, MD, PhD: Electrocore (Other Activities) (Research Grant or Support)
Annika Ehrlich, MS: Allergan (Speaking and Teaching) (Consulting Fees (e.g., advisory boards)) Currax Pharmaceuticals(Membership on Advisory Committees or Review Panels) (Consulting Fees (e.g., advisory boards)) Electrocore (Other Activities) (Research Grant or Support) Eli Lilly (Speaking and Teaching) (Consulting Fees (e.g., advisory boards)) Impel NeuroPharma(Membership on Advisory Committees or Review Panels) (Consulting Fees (e.g., advisory boards))
Henna Sawhney, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mira Parekh, PharmD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Morris Levin, MD: Alder (Consulting) (Consulting Fees (e.g., advisory boards)) Allergan (Consulting) (Consulting Fees (e.g., advisory boards)) Amgen (Consulting) (Consulting Fees (e.g., advisory boards)) Currax (Consulting) (Consulting Fees (e.g., advisory boards)) Percept (Consulting) (Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds)) Revance (Consulting) (Consulting Fees (e.g., advisory boards)) Theranica (Consulting) (Consulting Fees (e.g., advisory boards), Honoraria) Upsher-Smith (Consulting) (Consulting Fees (e.g., advisory boards))
